Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity and to Explore the Pharmacodynamics of CDP7657 Administered in Healthy Subjects and in SLE Patients.

To evaluate safety, tolerability, pharmacokinetics and immunogenicity of CDP7657

Inclusion Criteria:

• Healthy Volunteers and subjects with SLE

Exclusion Criteria:

• Severe neuropsychiatric or severe renal SLE
• History of chronic, recurrent, or recent severe infection
• Significant hematologic abnormalities
• History of cancer, heart failure, renal disease, liver disease or other serious illness